Adherex Technologies (FENC) to Release Earnings on Wednesday

Adherex Technologies (NASDAQ:FENC) is expected to be releasing its Q4 2025 results before the market opens on Wednesday, April 1st. Analysts expect the company to announce earnings of $0.0423 per share and revenue of $14.7490 million for the quarter. Individuals can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Tuesday, March 24, 2026 at 8:30 AM ET.

Adherex Technologies (NASDAQ:FENC) last posted its quarterly earnings data on Tuesday, March 24th. The company reported ($0.17) earnings per share for the quarter, missing analysts’ consensus estimates of $0.01 by ($0.18). The firm had revenue of $13.78 million during the quarter, compared to analysts’ expectations of $14.73 million. On average, analysts expect Adherex Technologies to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Adherex Technologies Trading Down 19.2%

Shares of NASDAQ:FENC opened at $6.02 on Wednesday. The stock has a 50 day moving average of $7.91 and a 200 day moving average of $8.14. The company has a market cap of $206.85 million, a PE ratio of -26.17 and a beta of 0.75. Adherex Technologies has a 12-month low of $4.68 and a 12-month high of $9.92.

Adherex Technologies News Roundup

Here are the key news stories impacting Adherex Technologies this week:

• Neutral Sentiment: Short interest prints showed 0 shares and a 0.0 days-to-cover ratio across multiple March filings — figures appear inconsistent or erroneous and are unlikely to reflect real short activity; this data glitch can add volatility but doesn’t indicate bearish conviction on its own.
• Neutral Sentiment: A GlobeNewswire business update reporting strong PEDMARK ® product sales and record annual revenue pertains to Fennec Pharmaceuticals (ticker FENC) and may have been conflated with Adherex in some feeds, adding to ticker-level noise. Fennec Press Release
• Negative Sentiment: Adherex reported Q4 EPS of ($0.17), missing the consensus of $0.01, and revenue of $13.78M vs. estimates of $14.73M — a clear earnings and top-line miss that explains selling pressure. Earnings/Transcript Press Release
• Negative Sentiment: Analyst coverage noted a larger-than-expected quarterly loss (Zacks cited a loss vs. estimates), reinforcing the market reaction to the earnings miss. Zacks Article
• Negative Sentiment: A Johnson Fistel notice invites Fennec Pharmaceuticals shareholders to contact the firm about potential securities claims — the announcement targets Fennec (same ticker) and could be misattributed to Adherex, amplifying sell pressure due to legal‑risk headlines even if not applicable. Legal Notice

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the stock. Piper Sandler initiated coverage on shares of Adherex Technologies in a report on Friday, January 9th. They set an “overweight” rating and a $18.00 price target on the stock. Zacks Research upgraded shares of Adherex Technologies from a “strong sell” rating to a “hold” rating in a research report on Friday, December 12th. Weiss Ratings restated a “sell (d-)” rating on shares of Adherex Technologies in a research note on Thursday, January 22nd. Wall Street Zen lowered Adherex Technologies from a “strong-buy” rating to a “buy” rating in a research note on Saturday, March 14th. Finally, B. Riley Financial started coverage on Adherex Technologies in a research report on Thursday, February 12th. They issued a “buy” rating and a $16.00 price objective on the stock. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Adherex Technologies currently has a consensus rating of “Moderate Buy” and a consensus price target of $15.25.

Insider Buying and Selling at Adherex Technologies

In related news, Director Rosty Raykov sold 10,349 shares of the firm’s stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $7.76, for a total transaction of $80,308.24. Following the completion of the transaction, the director directly owned 98,477 shares of the company’s stock, valued at approximately $764,181.52. This trade represents a 9.51% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 10.98% of the company’s stock.

Institutional Trading of Adherex Technologies

An institutional investor recently bought a new position in Adherex Technologies stock. AQR Capital Management LLC acquired a new stake in shares of Adherex Technologies Inc. (NASDAQ:FENC) in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 10,897 shares of the company’s stock, valued at approximately $66,000. Institutional investors own 55.51% of the company’s stock.

About Adherex Technologies

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc and changed its name to Fennec Pharmaceuticals Inc in September 2014. Fennec Pharmaceuticals Inc was founded in 1996 and is based in Research Triangle Park, North Carolina.